BIO-RAD LABORATORIES, INC. BIO

About BIO-RAD LABORATORIES, INC. (BIO): stock profile, AI score and financials

BIO-RAD LABORATORIES, INC. (BIO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BIO at 50.1/100 on a composite quality score built from its SEC filings, placing it at rank #1,636 of 2,925 stocks — the bottom half of the AI-ranked universe. BIO scores in the top quartile across earnings quality (85.8). Areas of concern include institutional flow (11.8) and revenue growth (26.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 37.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), BIO-RAD LABORATORIES, INC. reports quarterly revenue of $651.0M, net income of $371.4M, an operating margin of 11.2%. Top institutional holders of BIO by reported 13-F value include First Eagle Investment Management, BlackRock, DIMENSIONAL FUND ADVISORS, based on the most recent SEC filings. BIO trades on the NYSE exchange and files with the SEC under CIK 12208. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BIO-RAD LABORATORIES, INC. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 12208 →